SK Bioscience
https://www.skbioscience.co.kr/kr/main
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From SK Bioscience
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
Will The Dark Tunnel For Korean Biopharmas End In 2023?
Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.
Korea Q3 Roundup: Record Quarter For Hanmi, Daewoong, Boryung
Aside from what was generally a strong quarter for South Korean biopharma firms, Hanmi faces mixed news for its US pipeline, Daewoong’s Fexuclue and Nabota expand their market presence, Boryung builds its oncology business and SK Bioscience unveils an updated growth strategy.
How IVI Is Helping To Shape Korea’s Vaccine Ambitions
International Vaccine Institute Director General Jerome Kim talks to Scrip about the significance of South Korea's vaccine hub strategy and IVI's role, as well as the wider progress in the sector in the country.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice